Cargando…
Suvorexant improves intractable nocturnal enuresis by altering sleep architecture
Little is known about sleep-based approaches to the treatment of nocturnal enuresis (NE). This report is the first to describe the successful use of suvorexant, an orexin receptor antagonist, in a 12-year-old boy with intractable NE. With suvorexant, the frequency of NE gradually decreased from 14 o...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970267/ https://www.ncbi.nlm.nih.gov/pubmed/33727289 http://dx.doi.org/10.1136/bcr-2020-239621 |
_version_ | 1783666402316517376 |
---|---|
author | Matsumoto, Tohru |
author_facet | Matsumoto, Tohru |
author_sort | Matsumoto, Tohru |
collection | PubMed |
description | Little is known about sleep-based approaches to the treatment of nocturnal enuresis (NE). This report is the first to describe the successful use of suvorexant, an orexin receptor antagonist, in a 12-year-old boy with intractable NE. With suvorexant, the frequency of NE gradually decreased from 14 of 14 days (100%) to 5 of 14 days (35.7%). Sleep polysomnography indicated that rapid eye movement (REM) sleep increased from 101.5 min (19.9%) before suvorexant to 122.1 min (24.9%) with suvorexant. Furthermore, N2 increased from 233 min (45.6%) to 287.5 min (58.7%) during non-REM sleep. In contrast, N3 decreased from 160 min (31.3%) to 65 min (13.3%) during non-REM sleep. Suvorexant appeared to lighten the depth of sleep and alter sleep architecture. Although the application of an insomnia medication for treating NE seems paradoxical, suvorexant reduced the frequency of NE in patients with severe intractable NE. Thus, this treatment strategy warrants further examination. |
format | Online Article Text |
id | pubmed-7970267 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-79702672021-04-01 Suvorexant improves intractable nocturnal enuresis by altering sleep architecture Matsumoto, Tohru BMJ Case Rep Case Report Little is known about sleep-based approaches to the treatment of nocturnal enuresis (NE). This report is the first to describe the successful use of suvorexant, an orexin receptor antagonist, in a 12-year-old boy with intractable NE. With suvorexant, the frequency of NE gradually decreased from 14 of 14 days (100%) to 5 of 14 days (35.7%). Sleep polysomnography indicated that rapid eye movement (REM) sleep increased from 101.5 min (19.9%) before suvorexant to 122.1 min (24.9%) with suvorexant. Furthermore, N2 increased from 233 min (45.6%) to 287.5 min (58.7%) during non-REM sleep. In contrast, N3 decreased from 160 min (31.3%) to 65 min (13.3%) during non-REM sleep. Suvorexant appeared to lighten the depth of sleep and alter sleep architecture. Although the application of an insomnia medication for treating NE seems paradoxical, suvorexant reduced the frequency of NE in patients with severe intractable NE. Thus, this treatment strategy warrants further examination. BMJ Publishing Group 2021-03-16 /pmc/articles/PMC7970267/ /pubmed/33727289 http://dx.doi.org/10.1136/bcr-2020-239621 Text en © BMJ Publishing Group Limited 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Case Report Matsumoto, Tohru Suvorexant improves intractable nocturnal enuresis by altering sleep architecture |
title | Suvorexant improves intractable nocturnal enuresis by altering sleep architecture |
title_full | Suvorexant improves intractable nocturnal enuresis by altering sleep architecture |
title_fullStr | Suvorexant improves intractable nocturnal enuresis by altering sleep architecture |
title_full_unstemmed | Suvorexant improves intractable nocturnal enuresis by altering sleep architecture |
title_short | Suvorexant improves intractable nocturnal enuresis by altering sleep architecture |
title_sort | suvorexant improves intractable nocturnal enuresis by altering sleep architecture |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970267/ https://www.ncbi.nlm.nih.gov/pubmed/33727289 http://dx.doi.org/10.1136/bcr-2020-239621 |
work_keys_str_mv | AT matsumototohru suvorexantimprovesintractablenocturnalenuresisbyalteringsleeparchitecture |